Explore the evolving treatment strategies for metastatic clear cell renal cell carcinoma, highlighting innovative combination therapies and their efficacy.
September II 2025
During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.
During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.
During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE trial.
During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with non–small cell lung cancer.
During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with high PD-L1.
During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the KRAS-mutated non–small cell lung cancer population.
During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.
During a live event, Nelson J. Chao, MD, asked participants how they employ the currently approved treatments for chronic GVHD.
During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.
During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and axatilimab in patients with chronic graft-vs-host disease.